| P/E (FY) | — | Sales (TTM) | — |
| Earnings (TTM) | -$154.1M | ROE | — |
| Net Margin | — | ROIC | — |
| Debt / Equity | — | TD / EBITDA | — |
| EPS Growth 3Y | — | Sales Growth 3Y | — |
| Market Cap | $688.1M | Trading Days | 231 |
| 52W High | 14.87 |
| 52W Low | 7.01 |
| % Off High | −42.23% |
| YTD | −31.39% |
| Ann. Volatility (1Y) | 71.23% | Ann. Volatility (3Y) | 71.23% |
| Sharpe (1Y) | 0.18 | Sharpe (3Y) | 0.18 |
| Max Drawdown (1Y) | −48.14% | Max Drawdown (3Y) | −48.14% |
| Ticker | Name | Mkt cap | P/E |
|---|---|---|---|
| CTMX | CytomX Therapeutics, Inc. | $701.0M | — |
| CLYM | Climb Bio, Inc. | $703.7M | — |
| RIGL | RIGEL PHARMACEUTICALS INC | $712.3M | 2.0 |
| XOMA | XOMA Royalty Corp | $722.3M | 27.5 |
| MNPR | Monopar Therapeutics | $730.8M | — |
| DSGN | Design Therapeutics, Inc. | $741.4M | — |
| ACRS | Aclaris Therapeutics, Inc. | $744.4M | — |
| IRWD | IRONWOOD PHARMACEUTICALS INC | $625.5M | 25.3 |
| TENX | TENAX THERAPEUTICS, INC. | $619.6M | — |
| CYRX | Cryoport, Inc. | $764.6M | 10.8 |
| ANNX | Annexon, Inc. | $770.9M | — |
| Altimmune, Inc. |
| $581.5M |
| — |
